Industry Briefs: Feb. 20, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Feb. 20, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Apricus Bioscience’s wholly owned subsidiary NexMed (USA) has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to market Apricus Bio’s Vitaros (alprostadil) drug for treating erectile dysfunction. Read More

The Biomedical Advanced Research and Development Authority has awarded a contract worth up to $67 million for the development of a Tetraphase Antibiotic. Read More

Catalent Pharma Solutions has completed the acquisition of the clinical trials supplies business of Aptuit. Read More

FDA issued a Warning Letter to West-Ward Pharmaceticals for significant violations of cGMP regulations for finished pharmaceuticals. Read More

Mylan plans to change the name of its specialty subsidiary from Dey Pharma to Mylan Specialty. Read More

OncoPep has entered an exclusive license agreement with Dana-Farber for therapeutic multipeptide-vaccine technology for hematologic cancers. Read More

Quintiles plans to expand its commercial services in the Middle East and North Africa region through an agreement with Dayarn Pharma. Read More

Wyeth Pharmaceuticals (now part of Pfizer) seeks $960 million in damages from Sun Pharmaceutical for alleged patent infringement. Read More

People News

Amgen has named Michael Severino senior vice-president of global development and corporate chief medical officer. Read More

Astellas has appointed Charlotte M. E. Kremer as senior vice-president of its global medical affairs organization. Read More

Hospira has appointed Zena G. Kaufman as senior vice-president of quality. Read More

OSO BioPharmaceuticals has named Milton Boyer president of manufacturing. Read More

Patheon has appointed Stuart Grant as executive vice-president and chief financial officer. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here